Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | Director | January 02, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dermata Therapeutics, Inc.
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2036-01-01 | Direct | 2,500 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,500 · Balance 2,500 F1: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SPECTRUM PHARMACEUTICALS INC
Report date July 31, 2023 · Filed August 01, 2023
Section 16 reporting ended · disclosed 2023-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 1
1 source rowRow 1 · 2023-07-31 · Disposition to issuer · Disposed 27,380 · Balance 0 F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-31 · Disposition to issuer · Disposed 86,301 · Balance 0 F2: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger.
F2: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,
F3: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001493152-26-000694 · ownership.xml · derivative · entry 1 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 23:57 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001654954-25-000412 · section16.xml · derivative · entry 1 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-01-12 F1 · derivative.exercise_date: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 04, 2024 Filed Jan 6, 2024 02:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001654954-24-000292 · section16.xml · derivative · entry 1 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-03 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing January 4, 2024. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 17:22 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Disposition to issuerStock Option (Right to Buy) · Derivative | 86,301 | Not disclosed Strike: $1.13 | Not disclosed |
DisclosureSEC source: 0000899243-23-017680 · doc4.xml · derivative · entry 2 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 86,301 shares Expires not disclosed F2 · price: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3 · price: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. F2 · derivative.exercise_date: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3 · derivative.exercise_date: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. F2 · derivative.expiration_date: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3 · derivative.expiration_date: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 17:22 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Disposition to issuerCommon Stock, $0.001 par value | 27,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-017680 · doc4.xml · nonDerivative · entry 1 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 21:06 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock | 9,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-013529 · section16.xml · nonDerivative · entry 1 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,443 F1 · date: On October 6, 2022, the Reporting Person was granted 9,810 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 16:15 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 86,301 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-22-048497 · doc4.xml · derivative · entry 2 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,301 Underlying: Common Stock · 86,301 shares Expires 2032-08-31 F2 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of August 31, 2023, 2024 and 2025, respectively. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 16:15 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 27,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048497 · doc4.xml · nonDerivative · entry 1 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,380 F1 · shares: Represents restricted stock units ("RSUs") granted on August 31, 2022. One hundred percent (100%) of the total number of RSUs granted vest on the earlier of (i) June 22, 2023 or (ii) the date of the Company's 2023 Annual Meeting of Stockholders. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:10 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock, par value $0.0001 per share | 8,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-009456 · section16.xml · nonDerivative · entry 1 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,633 F1 · shares: On July 7, 2022, the Reporting Person was granted 8,602 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 23:13 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock, par value $0.0001 per share | 5,031 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-22-000564 · dermata_fm4apr72022.xml · nonDerivative · entry 1 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,031 F1 · shares: On April 7, 2022, the Reporting Person was granted 5,031 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 22:10 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000905718-22-000113 · dermata_fm4jan122022.xml · derivative · entry 1 Bradrick Brittany · CIK 0001904176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-11 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on January 12, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.